INTRODUCTION {#s1}
============

Traditional and complementary medicine (T&CM) strategies encompass health care practices and traditions that exist outside of the dominant biomedical health perspective, known as conventional medicine. Also termed Western medicine or biomedicine, conventional medicine is considered to include proven and experimental therapies that have arisen from an evidence-based paradigm or longstanding, commonly accepted medical practice. Traditional and complementary therapies often predate this paradigm, and in addition to health practices may represent essential cultural practices, particularly to indigenous peoples. The United Nations Declaration on the Rights of Indigenous Peoples codifies the right of indigenous peoples to "maintain their health practices"^[@B1](p9)^ and the WHO has recently published a 10-year strategy to encourage member states to develop policy to incorporate T&CM in health systems planning.^[@B2]^

In pediatric oncology, T&CM strategies are widely used^[@B3]^ but can present medical, legal, and ethical challenges to health practitioners. The use of T&CM may lead to uncertain interactions with conventional medicine (particularly when the use of T&CM is not disclosed), may delay therapies with proven effectiveness, and may be associated with abandonment of conventional therapy,^[@B4],[@B5]^ potentially increasing mortality risk. Ethical concerns include cost, effectiveness, and availability of T&CM.^[@B6],[@B7]^

Previous reviews^[@B3],[@B8]-[@B12]^ have looked at the prevalence of T&CM and attempted to synthesize and critically appraise the quality of T&CM research in pediatric cancer. Reported prevalence of use has ranged from 6% to 91%.^[@B3],[@B8]-[@B12]^ A recent review by Bishop et al^[@B3]^ identified heterogeneous study quality as a major barrier to research in T&CM. No studies to date have examined the use of T&CM in pediatric oncology globally by region, in relation to country income level or indicators of health system functioning. In areas where access to conventional medical treatments may be limited by availability of practitioners, cost, or distance, T&CM practices may be the primary health system used.^[@B13]^

The primary objectives of this systematic review were to describe estimated prevalence of T&CM use by country income group, types of T&CM used, reasons for use, perceived effectiveness, and disclosure of T&CM use to the oncology treating team. Secondary objectives included documenting treatment delays or abandonment related to T&CM use, assessing family characteristics associated with higher rates of T&CM use, and analyzing T&CM use in each country relative to national indicators of health expenditure per capita and physician availability.

METHODS {#s2}
=======

Data Sources and Searches {#s3}
-------------------------

We adhered to standard protocols for preparing and reporting this systematic review.^[@B14],[@B15]^ This review was registered a priori with the PROSPERO registry (CRD42015017295). We searched Medline, Embase, CINAHL, Global Health, PsycInfo, Allied and Complementary Medicine Database (AMED), the Cochrane Database of Systematic Reviews, and FirstSearch ProceedingsFirst from the date of inception of each database through February 20, 2016. Attempts were made to contact authors for additional information where appropriate. Keyword and text word searching were performed with all relevant terms, controlling for different spellings, synonyms, and truncations. The search strategy was reviewed by all authors as well as a library scientist. Bibliographies of included articles were reviewed for additional references. The search strategies can be viewed in the Data Supplement.

Study Selection and Data Abstraction {#s4}
------------------------------------

Inclusion criteria defined a priori comprised studies concerning children younger than age 18 years in at least 10% of participants, active treatment of cancer, and use of any type of T&CM as defined by the National Center for Complementary and Alternative Medicine, with or without the use of conventional therapy.^[@B16]^ Prayer was included as a T&CM because of its often integral role in traditional medicine strategies. Exclusion criteria defined a priori comprised a lack of pediatric oncology--specific outcomes reported, children not on active treatment in \> 50% of participants, and case reports. All other study types were included. There were no language exclusions.

Two reviewers (C.D. and S.M.) independently reviewed all references. Potentially relevant publications were retrieved for full-text review. Final inclusion was determined by consensus.

Data were independently abstracted by two reviewers (C.D. and S.M.) using a standardized form.^[@B17]^ Papers not in English had data abstracted by pediatric oncology health care professionals whose native language was the language of the study.

Outcomes {#s5}
--------

The primary objective of our study was to describe T&CM use stratified by country income level. The prevalence of T&CM use, types of T&CM used, reasons for use, perceived effectiveness of T&CM, and prevalence of disclosure of T&CM use to the treating oncology team were measured by self-report or parental proxy report in included studies. All modalities and reasons for T&CM use reported in the primary studies were recorded in data abstraction, but only the top five were reported. In addition, any reported use of T&CM for cancer cure was specifically noted. Any papers that reported on abandonment of therapy, delay in diagnosis, or initiation of therapy were recorded. Characteristics associated with T&CM use as captured in the primary studies were listed.

Countries were stratified based on country income into four strata using the World Bank country income classification^[@B18]^: low-income countries (LIC), lower-middle income countries (LMIC), upper-middle income countries (UMIC), and high-income countries (HIC).

Secondary analyses related T&CM use in each country to total (public and private) health expenditure per capita per year (in current US dollars) and physicians per 1,000 people.^[@B18]^ Average per capita spending on health expenditure is \$1,008 as per the WHO^[@B19]^; therefore, health expenditures were categorized as \< \$1,008 per capita versus ≥ \$1,008 per capita. A second analysis was done using a cutoff of \$44 per capita, which represents the minimum spending per person per year needed to provide basic, life-saving services as per the WHO.^[@B19]^ With regard to physicians per capita, a cutoff of 2.3 physicians per 1,000 people was used in keeping with the WHO Millennium Development Goals physician benchmark.^[@B20]^ Values published for each country were examined, and the most recent value available was used.^[@B21],[@B22]^

Data Synthesis and Analysis {#s6}
---------------------------

We determined a priori, on the basis of anticipated heterogeneity of data, that a meta-analysis would not be appropriate^[@B3]^; in lieu, it was determined that providing weighted mean estimates per country would allow a meaningful quantification of estimates. A weighted mean prevalence by number was used to synthesize data from countries with more than one published estimate of T&CM use. Significance between prevalence of use and income levels, physicians per capita, and health expenditure, as well as between median rates of T&CM use as cure for cancer and proportion reporting disclosure relative to country income levels, were determined using Kruskal-Wallis one-way analysis of variance. All statistical analyses were performed using the SAS statistical program (SAS-PC, version 9.4; SAS Institute, Cary, NC). All tests of significance were two-sided. Statistical significance was defined as *P* \< .05.

Quality Assessment {#s7}
------------------

Study quality was assessed using the T&CM in pediatric oncology--specific Quality Assessment Tool (QAT).^[@B3]^ We measured agreement in QAT scores using a weighted Cohen κ and percentage of agreement.^[@B24]^ QAT scores were not completed for articles in languages other than English.

RESULTS {#s8}
=======

[Figure 1](#F1){ref-type="fig"} illustrates the flow diagram of trial identification and selection on the basis of the PRISMA template. A total of 3,756 studies were screened. Sixty-five studies met inclusion criteria, but only 59 studies were included in the quantitative synthesis, because several studies published multiple papers examining the same data set,^[@B25]-[@B30]^ and there were two studies where conference abstracts had not been identified in screening to contain the same material as the eventual paper.^[@B31]-[@B34]^ A total of 61 data sets were included, because one study^[@B35]^ published data from an LMIC, UMIC, and HIC, and these were handled as separate data sets in the analysis. One study was identified through bibliographic reviews.^[@B32]^ Thirty-four different countries were represented within the data set, with a range of one to 10 studies for each country. There were two data sets from LIC, seven from LMIC, 13 from UMIC, and 39 from HIC. [Table 1](#T1){ref-type="table"} presents the prevalence and characteristics of use across countries. Most studies were published in English, with three studies in French and one each in Polish, Hungarian, Chinese, and German.
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Prevalence Estimates of the Use of T&CM {#s9}
---------------------------------------

Prevalence of use of T&CM ranged from 6% to 100%. The lowest (6%, N = 66) was reported in the United States in 1983.^[@B36]^ Since the first study published on T&CM use in pediatric oncology in 1977, prevalence of use in the United States has ranged from 6% to 84%, with no consistent trend over time.^[@B36]-[@B45]^ The highest prevalence of use of T&CM (100%, N = 41) was reported in Saudi Arabia in 2011.^[@B46]^ There are no other published estimates from Saudi Arabia meeting inclusion criteria for comparison; however, in other Middle Eastern countries prevalence of T&CM use ranged from 15% to 65%.^[@B33],[@B34],[@B47]^

The median estimated prevalence of use was 77% (± 25%) in LIC, 67% (± 19%) in LMIC, 60% (± 26%) in UMIC, and 47% (± 20%) in HIC. Because there were only two LIC studies, the LIC and LMIC were considered together for the purposes of this analysis; median prevalence of use in LIC/LMIC was 67% (± 19%). A significant difference was observed between the LIC/LMIC, UMIC, and HIC median rates of use (*P* = .02).

Median prevalence of use of T&CM was significantly higher among countries that spent \< \$1,008 per capita at 63% (± 21%) than among those who spent \$1,008 or more at 46% (± 19%; *P* = .01). Median prevalence of use of T&CM in countries where the per capita health expenditure was \< \$44 was 60% (± 8%, N = 3), and it was 56% (± 22%, N = 31) in those where spending was ≥ \$44 per capita (*P* = .55). Among countries with fewer than 2.3 physicians per 1,000 citizens, median prevalence of use was 61% (± 16%) compared with 46% (± 24%) among nations with at least 2.3 physicians per 1,000 citizens (*P* = .02).

Type of T&CM Used {#s10}
-----------------

Fifty-seven out of 61 data sets (93%) reported on the types of T&CM used. Commonly used modalities included oral supplements and dietary changes, alternative medical systems (including traditional healers), and spiritual treatments including faith healing, prayer, and religious practices. Traditional healers were used in all income groups, reported in Kenya (LMIC),^[@B48]^ Cameroon (LMIC),^[@B49]^ Malaysia (UMIC),^[@B50]^ and Israel and Canada (HIC).^[@B51],[@B52]^ Homeopathy use was reported exclusively in UMIC and HIC, most commonly in European countries. A detailed list of T&CM treatments used is presented in the Data Supplement.

Reasons for T&CM Use {#s11}
--------------------

Thirty-nine data sets (64%) reported on reasons for T&CM use. Common reasons cited for the use of T&CM included curing the cancer, doing everything possible for their child, boosting the immune system, improving general well-being, and treating adverse effects of conventional therapy. The median rate of T&CM use for cure of cancer reported in LIC/LMIC was 53% (± 25%), in UMIC was 25% (± 10%), and in HIC was 20% (± 27%), although these differences did not reach significance (*P* = .23).

Perceived Effectiveness of T&CM {#s12}
-------------------------------

Effectiveness was reported in 29 out of 61 (48%) of the data sets, with most users reporting T&CM as being effective or very effective (Data Supplement). Effectiveness was measured as perceived effectiveness by users/parents; no studies reported objective measures. Most studies reported very high overall effectiveness of T&CM, with only four studies reporting general rates \< 50%.^[@B36],[@B55],[@B59],[@B60]^ In particular, one American^[@B36]^ study with four T&CM users noted that none reported that the T&CM treatments were effective.

Disclosure of T&CM Use {#s13}
----------------------

Disclosure of T&CM use to the oncology treating team ranged from 8% (Turkey)^[@B59]^ to 78% (Germany)^[@B29],[@B30]^ and was reported in 37 of 61 data sets (61%). Median rates of disclosure differed significantly between LIC/LMIC, UMIC, and HIC, with rates of 21% (± 7%), 32% (± 22%), and 45% (±15%), respectively (*P* = .03). Reasons for nondisclosure were reported by eight studies,^[@B45],[@B48],[@B60]-[@B65]^ including four HIC,^[@B45],[@B60],[@B64],[@B65]^ two UMIC,^[@B61],[@B62]^ and two LIC.^[@B48],[@B63]^ Examples of reasons for nondisclosure included belief that T&CM was nontoxic,^[@B64]^ fear of the physician's reaction,^[@B48],[@B61]-[@B63],[@B65]^ belief that the medical staff lacked knowledge of T&CM,^[@B45],[@B60]^ and the physician did not ask.^[@B45],[@B61]^

T&CM and Delay in Diagnosis or Treatment or Abandonment of Treatment {#s14}
--------------------------------------------------------------------

Three studies reported abandonment of conventional therapy related to T&CM use. In a study from British Columbia, Canada, 5% (eight of 156) of T&CM users chose alternative medicine instead of conventional care.^[@B66]^ Similarly, 4% (two of 46) of T&CM users in a Taiwanese study abandoned conventional treatment of folk remedies.^[@B67]^ A study from Malaysia reported three patients abandoning conventional medicine for T&CM (unspecified if these patients were adults or children).^[@B61]^ Outcomes were reported only for the Taiwanese study, in which both patients relapsed and were rehospitalized.

Four studies reported on delays in conventional treatment to pursue T&CM: one of 92 patients from Quebec, Canada,^[@B68]^ 7% (three of 41) in Saudi Arabia,^[@B46]^ 9% (four of 45) in Jordan,^[@B33]^ and 13% (three of 13) in Malaysia.^[@B69]^ None of the included studies reported specific outcome data for patients who delayed conventional treatment of T&CM.

Associations With T&CM Use {#s15}
--------------------------

Details of the family characteristics associated with reported T&CM use are listed in the Data Supplement. Associations with T&CM use were reported almost exclusively by studies from HIC. Several studies reported higher rates of T&CM use associated with increasing parental education^[@B29],[@B31],[@B70],[@B71],[@B72]^ and higher socioeconomic status.^[@B73]^ Only one study from Guatemala reported an analysis of this association in an LMIC.^[@B31]^ Similarly, only studies from HIC reported a statistically significant association between T&CM use and dissatisfaction with conventional treatments (United States^[@B40]^ and Singapore^[@B64]^) and parental T&CM use (United States,^[@B43],[@B44]^ Canada,^[@B74]^ and the Netherlands^[@B75]^). One study from Lebanon reported higher rates of T&CM use associated with a family history of leukemia.^[@B47]^

Quality Assessment Tool Scores {#s16}
------------------------------

QAT scores determined by consensus for the included studies are listed in the Data Supplement. Scores ranged from 6 to 15, with a median score of 11.5 out of 18 (± 2.5). Interrater reliability demonstrated excellent agreement^[@B76]^ by the weighted Cohen κ statistic of 0.89 (95% CI, 0.81 to 0.97), with 72% agreement in raw scores.

DISCUSSION {#s17}
==========

The use of T&CM in pediatric oncology is common and widespread. We demonstrate significantly different reported rates of use of T&CM among patients in LIC/LMIC, UMIC, and HIC, and as related to measures of health system resources. We also describe differences in frequency of disclosure of T&CM use to oncology treating teams among patients in LIC/LMIC, UMIC, and HIC; T&CM types used; and reasons for use. Among the limited studies that reported on outcomes of T&CM use, T&CM was associated with abandonment of treatment and delay in diagnosis or treatment of cancer in seven out of 61 data sets in a range of countries. These important characteristics of T&CM use must be used to help guide advocacy and intervention strategies for children with cancer worldwide.

In LIC/LMIC median reported rates of use are significantly higher than in UMIC and HIC. Evidence to explain this difference is limited. In many LIC/LMIC, patients must pay to access conventional health care, and in one study from Cameroon the lower cost of seeking care from a traditional healer was reported as a reason for use.^[@B49]^ Beyond this, other hypothesized reasons include other elements of cost, health beliefs, and trust. Families' comfort with T&CM practitioners may be higher than with hospitals because of the importance practitioners have in the local community.^[@B77]-[@B79]^ Oncologic care in LIC/LMIC is typically delivered at larger centers that may be a significant distance from the homes of patients; as such, travel may be limited by access to vehicles and associated costs, including lost family income.^[@B80]^ Furthermore, in areas where punitive practices such as hospital detention exist, families may be deterred from presenting to hospitals.^[@B81]^ In contrast, the prevalence of use of T&CM in HIC was associated with measures of higher socioeconomic status (including parental education), dissatisfaction with conventional treatment, and parental T&CM use. Further research into context-specific rates and reasons for use of T&CM is required.

Our results demonstrated several reports of abandonment of conventional therapy for T&CM. Although a recent meta-analysis reported rates of abandonment of 29% for children with acute leukemia in LMIC,^[@B82]^ abandonment can also affect patients in UMIC and HIC with prevalence of as high as 2%^[@B82]^ to 5%.^[@B66]^ Physicians in all settings must be aware of the potential for patients to prefer T&CM over conventional therapy and of the local legal, ethical, and moral norms, particularly as these may be in evolution.^[@B6],[@B83]^ The rates of abandonment and delay of treatment due to T&CM in LIC/LMIC are likely higher than what is currently reported in the literature, as there may be a large number of patients with oncologic conditions who are being managed solely by traditional practitioners, who never present to an oncology treating team.^[@B13],[@B84]^ Unfortunately, few studies reported on this important issue. Future research should attempt to quantify the rates of nonpresentation, abandonment (including up-front refusal of therapy), and/or delay of conventional therapy for T&CM.

Awareness of the high rates of T&CM use is essential to guide clinical practice. Pediatricians and oncology providers must learn to work alongside T&CM practitioners across all settings. This is particularly true in LIC and LMIC, where the use of traditional medicines is widespread and embedded in cultural practices.^[@B2]^ Success has been demonstrated in the treatment of HIV/AIDS in sub-Saharan Africa by integrating traditional health care practitioners in the treatment team.^[@B85]^ Harnessing the existing health systems that exist through T&CM paradigms in all resource settings could lead to greater patient satisfaction through the delivery of family-centered, culturally accessible care. Moreover, it is plausible that T&CM may provide relief for symptom management, particularly in areas with limited or inconsistent access to supportive care medications.

Our study has several limitations. Despite the fact that the highest prevalence of use may exist in LIC and LMIC, there is a paucity of data available from these settings. We attempted to address this anticipated shortcoming by not including a language limitation in our search criteria and including data from conference abstracts. We were not able to assess the quality of data in non-English studies, limiting our ability to comment on study quality. Almost all studies published are cross-sectional studies and do not describe the use of T&CM throughout the continuum of care. As previously reported by Bishop et al,^[@B3]^ there is a wide range in the quality of data available. In addition, there is intracountry variability in estimates over time that limits our ability to make accurate estimates of prevalence. Many countries have only single-site estimates that do not necessarily present a representative estimate of true practices in the country. UMIC and HIC prevalence of use may be under-represented, particularly in countries where a T&CM strategy may be part of the dominant health system. For example, there were no reports meeting our study inclusion criteria for estimates of prevalence published from China (UMIC), where traditional Chinese medicine is embedded within the dominant medical system.^[@B86]^ A further limitation is the lack of validated surveys and consistent methodology. Data reported represent heterogeneous patient inclusion with different diagnoses, prognoses, and time points represented. All data available were obtained from patients who at least sought out and received some conventional medical care, and therefore the generalizability is limited.

The use of T&CM in pediatric oncology is common worldwide, with higher median prevalence estimates in lower-income countries. Further research is needed to define the cultural and regional influences on T&CM use and attempt to prospectively assess the impact of T&CM on patient outcomes. Treatment planning and delivery in all income settings must attempt to integrate an awareness of T&CM practices to better provide holistic care to patients and to work to prevent abandonment and delay of therapy.
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